Results 31 to 40 of about 22,854 (176)
Italian Patients Journey for Gene Therapy in Haemophilia A
Haemophilia, EarlyView.ABSTRACT Introduction Gene therapy (GT) provides sustained FVIII levels without repeated infusions in Hemophilia A (HA) patients thus overcoming a major limitation of replacement therapy. However, issues remain e.g., patient selection criteria, duration and variability of transgene expression, quality of life and long‐term safety.
Giovanni Di Minno +19 more
wiley +1 more source
Real‐World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond
International Journal of Cancer, Volume 159, Issue 7, Page 1780-1787, 1 October 2026.Progression after anti‐PD‐1‐based therapy is a predominant scenario in metastatic melanoma. However, real‐world data informing treatment of metastatic melanoma in later lines remains scarce. This retrospective nationwide, population‐based cohort study shows in a real‐world setting that nivolumab plus ipilimumab can induce durable responses beyond the ...
Yago Garitaonaindia +11 more
wiley +1 more source
EMBO Molecular Medicine, 2017 The cell fate determinant Numb is frequently downregulated in human breast cancers (BCs), resulting in p53 inactivation and an aggressive disease course.
Daniela Tosoni +8 more
doaj +1 more source
The Journal of Pathology: Clinical Research, Volume 12, Issue 5, September 2026.Abstract B‐cell precursor acute lymphoblastic leukemia (preB‐ALL) is characterized by pathogenic variants currently used in precision oncology. However, the mutational landscape of Mexican children with preB‐ALL has not yet been thoroughly explored and defined in terms of the clinical significance.
Daniel Martínez Anaya +10 more
wiley +1 more source
American Journal of Hematology, Volume 101, Issue 9, Page 2258-2268, September 2026.ABSTRACT Quizartinib is a tyrosine kinase inhibitor with single agent activity in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and has demonstrated efficacy in first‐line therapy when combined with intensive chemotherapy in both FLT3 ITD‐negative and positive AML.
Teresa Bernal +29 more
wiley +1 more source
A COMPLEX CARE: COMMUNICATING BAD NEWS IN ONCOLOGY
Revista de Pesquisa Cuidado é Fundamental Online, 2012 Objetivos: Analisar as produções científicas que abordam a temática de más notícias em oncologia e discutir a comunicação das mesmas nesta área. Método: Trata-se de uma revisão bibliográfica de abordagem qualitativa.
Raquel de Abreu Pinheiro e Souza +1 more
doaj +1 more source
Environmental Toxicology, Volume 41, Issue 9, Page 709-729, September 2026.ABSTRACT Prostate cancer (PCa) is an endocrine‐related cancer highly dependent on androgenic signaling. Beyond hormone dependence, extrinsic factors play a significant role in the risk of developing PCa, which raises concern about the influence of environmental compounds such as endocrine‐disrupting chemicals (EDCs). Tributyltin (TBT) is an EDC used in
Mariana Feijó +9 more
wiley +1 more source
Cancer Medicine, Volume 15, Issue 8, August 2026.ABSTRACT Background Cervical cancer (CC) is a main malignancy affecting women globally, with a high mortality rate. Chemoradiotherapy resistance is a significant factor in determining treatment outcomes, and prognostic biomarkers are essential for the appropriate selection of therapeutic strategies.
Angelo Borges de Melo Neto +14 more
wiley +1 more source
Breast Skin Lesions in a 79‐Year‐Old Woman
JEADV Clinical Practice, EarlyView.
Javier Lorenz‐Dolz +4 more
wiley +1 more source
Cancer, Volume 132, Issue 15, 1 August 2026.Abstract Background Vobramitamab duocarmazine is an investigational antibody–drug conjugate (ADC) targeting B7 homolog 3 (B7‐H3) with a cytotoxic duocarmycin‐based DNA‐alkylating payload. This study evaluated its safety and antitumor activity in advanced solid tumors.
Eugene Shenderov +20 more
wiley +1 more source